Skip to main content
. 2020 Sep 30;6(3):235–242. doi: 10.5114/ceh.2020.99517

Table 5.

Differences in clinical and laboratory variables between patients with liver cirrhosis alone and patients with liver cirrhosis and HCC

Variable Patients without HCC C(= 7) = 7)Pats with HCC ients with HCC = 36) p
= 36)pBMI (kg/m2n (Q1-Q3) , medi28.0-33.5) 29.0 (27.8-32.2) n (Q2
1-Q3)29.0 (28.0-33.5)29.0 (27.8-32.2)0.691-Q3) 2Age (ye) 59.0 (57.0-65.2) rs947
), median (Q1-Q3women 2 (28.6) 59.0 (58) 1.5-0
70.0)59.0 (57.0-65.2)0.947Sex, n (Q1-Q3) (%) of wome) 0.4 (0.2-0.6) 2 (20
8.6)10 (27.8)1.00SD 0.5 aspin (ng/ml9 0.870
, median (Q1-Q3)0.1 (0.1-0.2)0.4 (0.2) -0.6(2.0-2.9) )0.09.5) 0.669
Visfatin (ng/ml), mean ±SD4.4 ±-Q3) 25.0 (22.7-43.6) .6.5 (24.1-48.6) 0.733
4.3 ±1.90.870Irisin () μg/ml6) ), median ) (Q1-2
Q3)2.1 (2.0-2.9)2.3 (1.7-) 3.528.6%) 12 (33.3%) 0.669Bet0
atrophin (ng/ml), m) edi14.3%) 12 (33.3%) n (Q9
1-Q3)25.0 (22.7-43.6)36.5 (24.1-48.6)0.731-Q3) 58.0 (36.0-86.5) Insulin (ng/ml2) 0.818
, median (Q1-Q3)0.7 (0.4) -8.0 (56.5- 99.5) 1.6-139.5) 0.831
1.0 (0.5-1.3±SD 119.7 ±97.0 0.478 ±80.8 0.524
Type 2 diabetes, n (Q1-Q3) (%0 (37.5-122.0) 95.5 (64.2-170.8) 2 (23
8.6%)12 (33.3%)1.00Q1-Q3) 85.1 (77.2-140.7) Hypertensio2-179.5) 0.023
, n(%)1 (14.3%) 77.0 (49.0-120.9) 12 (33.3%.9-133.0) 0.300
0.579ALT (IU/l), mediQ3) 39.7 (32.6-47.6) n (Q1-Q3.2-45.2) 0.543
58.0 (36.0-86.5)60.0 (40.0-91.2±SD 69.4 ±15.1 0.81 ±13.8 0.402
AST (IU/l), median (Q1-Q3)68.0 (56.5- 99.5)96.5 (51 .8-139.8 5)01 .8396
1ALP (IU/l), mean ±SD 3.3 ±0.5 119.7 ±5 97.53
0145.8 ±80.80.524GGTP (IU) /l7 (4.4-14.9) 42.1 (15.0-188.4) , me5
dian (Q1-Q3)50.0 (37.5-122.0)95.5 (64) .2-170.8-7.3) 3.1 (2.2-4.6) 0.189
3TChol (mg/ml (Q1-Q3) 10.6 (6.2-32.7) , medi6.9-25.3) 0.717

BMI – body mass index, ALT – alanine aminotransferase, AST – aspartate aminotransferase, WBC – white blood cell count, HGB – hemoglobin, ALT – alanine transferase, AST – aspartate transferase, ALP – alkaline phosphatase, GGTP – gamma glutamyl transpeptidase, TChol – total cholesterol, TG – triglycerides, HDL – high-density lipoprotein, PT – prothrombin time, AFP – α-fetoprotein, CEA – carcinoembryonic antigen, CA – cancer antigen